Advertisement
Screener

Biomea Fusion, Inc. (BMEA) Graph

BMEA Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $9.14M; Operating expenses $12.77M; Net income -$8.33M.
  • 2026-03-31: Revenue (m); Research and development $9.12M; Operating expenses $12.77M; Net income -$12.41M.
  • 2025-12-31: Revenue (m); Research and development $8.12M*; Operating expenses $11.72M*; Net income $4.61M*.
  • 2025-09-30: Revenue (m); Research and development $14.40M; Operating expenses $20.80M; Net income -$16.41M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$9.14M$12.77M-$8.33M
2026-03-31(m)$9.12M$12.77M-$12.41M
2025-12-31(m)$8.12M*$11.72M*$4.61M*
2025-09-30(m)$14.40M$20.80M-$16.41M
2025-06-30(m)$16.57M$21.28M-$20.74M
2025-03-31(m)$22.90M$29.71M-$29.26M
2024-12-31(m)$25.24M$30.07M-$29.30M
2024-09-30(m)$27.24M$34.04M-$32.79M
2024-06-30(m)$31.82M$38.90M-$37.28M
2024-03-31(m)$33.78M$41.06M-$39.06M
2023-12-31(m)$30.87M$37.33M-$34.88M
2023-09-30(m)$25.35M$31.12M-$28.43M
2023-06-30(m)$21.94M$27.66M-$24.89M
2023-03-31(m)$24.39M$30.03M-$29.05M
2022-12-31(m)$20.54M$26.28M-$25.31M
2022-09-30(m)$18.24M$23.48M-$22.89M
2022-06-30(m)$12.58M$17.47M-$17.26M
2022-03-31$1.07B$11.35M$16.40M-$16.37M
2021-12-31(m)$11.09M$14.74M-$14.71M
2021-09-30(m)$7.89M$12.64M-$12.61M
2021-06-30(m)$5.22M$8.44M-$8.40M
2021-03-31$1.07B$3.80M$5.86M-$5.85M
2020-12-31(m)$2.33M$3.50M-$3.50M
2020-09-30(m)$789.00K$1.14M-$1.14M
2020-06-30(m)$216.00K$295.00K-$293.00K
2020-03-31(m)$334.00K$398.00K-$398.00K

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30(m)$18.26M$25.54M-$20.74M
2025-06-30(m)$39.46M$50.99M-$50.00M
2024-06-30(m)$65.60M$79.96M-$76.34M
2023-06-30(m)$46.33M$57.69M-$53.94M
2022-06-30$1.07B$23.93M$33.87M-$33.62M
2021-06-30$1.07B$9.02M$14.29M-$14.25M
2020-06-30(m)$550.00K$693.00K-$691.00K

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30(m)$53.86M$71.79M-$66.41M
2024-09-30(m)$92.84M$114.00M-$109.12M
2023-09-30(m)$71.68M$88.81M-$82.37M
2022-09-30$1.24B$42.17M$57.36M-$56.51M
2021-09-30$1.07B$16.91M$26.93M-$26.86M
2020-09-30(m)$1.34M$1.83M-$1.83M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$61.98M$83.51M$0.00-$61.80M
2024-12-31$118.08M$144.07M$0.00-$138.43M
2023-12-31$102.55M$126.14M$0.00-$117.25M
2022-12-31$62.71M$83.63M$0.00-$81.83M
2021-12-31$28.00M$41.67M$0.00-$41.57M
2020-12-31$3.67M$5.33M$0.00-$5.32M
2019-12-31$1.09M$1.20M(m)-$1.20M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
Equillium, Inc. (EQ)United States$0.109B-11.27
GENELUX Corp (GNLX)United States$0.110B-3.83
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
ProMIS Neurosciences Inc. (PMN)$0.102B
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Anixa Biosciences Inc (ANIX)United States$0.096B